1562988-38-8 Usage
Description
(S)-5-amino-3,3-difluoro-piperidine-1-carboxylic acid benzyl ester is a chemical compound with potential pharmaceutical applications. It is an amino acid derivative that contains a piperidine ring and a benzyl ester group. The presence of the fluorine atoms confers unique chemical properties to the molecule, making it suitable for use in drug design and medicinal chemistry.
Uses
Used in Pharmaceutical Industry:
(S)-5-amino-3,3-difluoro-piperidine-1-carboxylic acid benzyl ester is used as a building block for the synthesis of novel pharmaceuticals with enhanced biological activity and improved pharmacokinetic properties. (S)-5-amino-3,3-difluoro-piperidine-1-carboxylic acid benzyl ester's unique chemical properties, including the presence of fluorine atoms and the benzyl ester group, make it a promising candidate for the development of new drugs for a variety of medical conditions.
Used in Drug Design and Medicinal Chemistry:
(S)-5-amino-3,3-difluoro-piperidine-1-carboxylic acid benzyl ester is used as a key component in drug design and medicinal chemistry. Its unique structure allows for targeted modifications to the molecule's properties, potentially leading to the creation of new drugs with specific therapeutic applications.
Further research and development of (S)-5-amino-3,3-difluoro-piperidine-1-carboxylic acid benzyl ester could lead to the creation of new drugs for a variety of medical conditions, making it a valuable asset in the pharmaceutical and medicinal chemistry industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1562988-38-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,6,2,9,8 and 8 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1562988-38:
(9*1)+(8*5)+(7*6)+(6*2)+(5*9)+(4*8)+(3*8)+(2*3)+(1*8)=218
218 % 10 = 8
So 1562988-38-8 is a valid CAS Registry Number.
1562988-38-8Relevant articles and documents
INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)
-
, (2018/02/28)
The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.
